Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Spinnovation Transfers its Entire Operation to Pivot Park

Published: Monday, January 13, 2014
Last Updated: Monday, January 13, 2014
Bookmark and Share
The new location has enabled Spinnovation to double the size of its facilities, to support the growth of its business.

Spinnovation Analytical BV has today announced the transfer of its entire operations to Pivot Park in Oss, the Netherlands. Since 2013, Spinnovation has collaborated with Pivot Park by supplying analytical services to life science companies based on the site. The new location has enabled Spinnovation to double the size of its facilities, to support the growth of its business. Furthermore, this new location will facilitate the development of GMP compliant services and expand Spinnovation’s analytical capabilities.

Spinnovation Analytical BV provides a range of analytical services for the pharmaceutical and biopharmaceutical industries. Having first opened laboratories and offices in Pivot Park in February 2013, Spinnovation has supported the park’s initiative for open access and exchange of knowledge by providing tenants at the site with access to advanced analytical technologies. Spinnovation offers innovative NMR-based testing and profiling methods, in addition to ESI-TOF MS, HPLCs, LC-SPE and ICP-OES applications. Spinnovation Biologics also offers unique services for biologics upstream development, including Spedia-NMR™ for spent cell media analysis and Spedia-Predict™ for troubleshooting bioprocessing issues.

Jules de Vet, interim Director of Pivot Park, commented, “Since their move here last year, Spinnovation has proved a valuable partner for Pivot Park and its tenants. We are delighted to hear that Spinnovation will be transferring their full operation and expanding their presence at Pivot Park and will be able to deliver even more analytical services to our tenants.”

Frederic Girard, CEO of Spinnovation Analytical, said, “We are very pleased with the success of our partnership with Pivot Park and we are thrilled to expand our presence here. With our larger facility, we can better cope with the growth of our services for our customers across Europe and the United States, while securing access to industry leading analytical applications for park tenants. Transferring our facility will enable us to capitalize on our success in 2013, work towards GMP-compliant assays and testing capabilities and continue to develop and grow our innovative analytical services during 2014 and beyond.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CEO Frederic Girard Joins Fellow Industry Experts for a QbD Round Table
New article on quality by design is now available online.
Friday, August 16, 2013
Spinnovation Expands in to the US
Spinnovation collaborate with Quantum Tessera in Pennsylvania.
Tuesday, April 17, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!